CONSUN PHARMA News

Bocom Intl: rates the Mainland pharmaceutical industry as "leading", focusing on innovative and consumer-driven targets.

Zhitong FinanceOct 17 09:53

Kangchen Pharmaceutical (1681.HK): 24H1 net profit to mother increased by about 15%, and the dividend rate in 24 is expected to exceed 10%

Aug 22 16:46

Kangchen Pharmaceutical (1681.HK): Performance continues to grow rapidly, and the leading value of traditional Chinese medicine in nephrology is undervalued

Aug 22 00:00

Kangchen Pharmaceutical (1681.HK): Revenue Growth Steady, Profitability to Distribute Interim Dividends Upwards

Aug 22 00:00

ANXIN INTERNATIONAL: First gives Consun Pharma (01681) a "shareholding" rating. Three products, including Rosuvastatin Capsules, are expected to be approved for listing in 2024.

Zhitong FinanceJun 21 16:27

Kangchen Pharmaceutical (1681.HK): Leading nephrology proprietary Chinese medicine leader with high dividends and accelerated performance can be expected

May 17 00:00

Kangchen Pharmaceutical (1681.HK): Significant advantages in the field of nephrology, performance continues to grow rapidly

Apr 8 00:00

Kangchen Pharmaceutical (1681.HK): Continued rapid growth in the field of nephrology

Mar 28 00:00

Kangchen Pharmaceutical (1681.HK): Deeply involved in the field of nephrology, rapid profit growth

國元國際Aug 25, 2023 00:00

Kangson Pharmaceutical (01681.HK): Annual performance is impressive, and the field of nephrology is developing in depth

興業證券Apr 17, 2023 14:57

Kangson Pharmaceutical (1681.HK): Deepening the field of nephropathy with continuous improvement in operating efficiency

國元國際Mar 23, 2023 00:00

Kangson Pharmaceutical (01681.HK): Steady revenue growth under the pandemic continues to deepen the nephrology sector

興業證券Sep 2, 2022 00:00

Kangson Pharmaceutical (1681.HK): The leading position in the nephrology field is stable and the performance is growing rapidly

國元國際Aug 26, 2022 00:00

Kangson Pharmaceutical (01681.HK): Annual performance was steady and the reform of Jade Pharmaceutical progressed smoothly

興業證券Apr 12, 2022 20:36

Kangson Pharmaceutical (1681.HK): Yulin Pharmaceutical's 21-year performance improvement trend has not changed

招商證券(香港)May 6, 2021 00:00

Kangson Pharmaceutical (01681.HK): The next catalyst: Yulin Pharmaceutical is expected to improve in 2021

招商證券(香港)Oct 12, 2020 00:00

Kangson Pharmaceutical (01681.HK): Jade Pharmaceutical's rectification effects are initially showing, and it is expected that it will usher in an inflection point in performance

第一上海Sep 8, 2020 00:00

Kangson Pharmaceutical (01681.HK): As the effects of the Jade Pharmaceutical marketing reform gradually became apparent, it is expected to usher in an inflection point in performance

第一上海May 11, 2020 00:00

Kangson Pharmaceutical (1681.HK): Down to earth and moving forward steadily

興業證券Mar 24, 2019 00:00

[Smart Investment] Kangson Pharmaceutical (1681.HK): 2018 performance is in line with expectations; valuation is underestimated

招銀國際Mar 21, 2019 00:00